Pre-exposure chemoprophylaxis for HIV: It is time

Retrovirology

Volumn 1, Issue , 2004, Pages

  Smith, Stephen M ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AFRICA SOUTH OF THE SAHARA; ARTICLE; BOTSWANA; CHEMOPROPHYLAXIS; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; SWAZILAND; VIRUS TRANSMISSION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEVELOPING COUNTRY; DRUG EFFECT; DRUG INDUSTRY; METHODOLOGY; PHYSIOLOGY; REVIEW; STATISTICS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; CHEMOPREVENTION; DEVELOPING COUNTRIES; DRUG INDUSTRY; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE;

EID: 4344676833     PISSN: 17424690     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-4690-1-16     Document Type: Article

References (29)

1. AIDS epidemic update December 2003 Geneva, UNAIDS/WHO 2003.
2. Desrosiers RC: Prospects for an AIDS vaccine. Nat Med 2004, 10:221-223.
3. Cohen J: Public health. AIDS vaccine still alive as booster after second failure in Thailand. Science 2003, 302:1309-1310.
4. Cohen J: HIV/AIDS. Vaccine results lose significance under scrutiny. Science 2003, 299:1495.
5. Pitisutithum P: Efficacy of AIDSVAX B/E Vaccines in Injecting Drug Use. 11th Conference on Retroviruses and Opportunistic Infections San Francisco 2004.
6. Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, Hoxie JA, Hunter E, Korber B, Landay A, Lederman MM, Lieberman J, McCune JM, Moore JP, Nathanson N, Picker L, Richman D, Rinaldo C, Stevenson M, Watkins DI, Wolinksky SM, Zack JA: Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004, 303:316.
7. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT: HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004, 5:233-236.
8. Smith SM: HIV CTL escape: at what cost? Retrovirology 2004, 1:8.
9. The 3 by 5 Initiative Geneva, World Health Organization 2004.
10. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, Heptonstall J, Ippolito G, Lot F, McKibben PS, Bell DM: A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997, 337:1485-1490.
11. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, Benveniste RE, Black R: Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995, 270:1197-1199.
12. Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N, Lifson JD, Morton WR: Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998, 72:4265-4273.
13. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180.
14. Paul SM, Burr CK, DiFerdinando GT: Updated recommendations for reducing vertical HIV transmission. N J Med 2003, 100:27-31; quiz 69-70.
15. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, Lutalo T, Li X, vanCott T, Quinn TC: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001, 357:1149-1153.
16. Fleck F: WHO admits its target on AIDS drugs may be unrealistic. Bmj 2004, 328:1151.
17. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM, Mmiro F, Jackson JB: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). Aids 2001, 15:1951-1957.
18. Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler MG, Mofenson LM, Mirochnick M, Mmiro F, Eshleman SH: Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. Aids 2000, 14:F111-5.
19. van Griensvan F, Keawkungwal J, Tappero JW, Sangkum U, Pitisuttithum P, Vanichseni S, Suntharasamai P, Orelind K, Gee C, Choopanya K: Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. Aids 2004, 18:295-301.
20. Montessori V, Press N, Harris M, Akagi L, Montaner JS: Adverse effects of antiretroviral therapy for HIV infection. Cmaj 2004, 170:229-238.
21. McLeod GX, Hammer SM: Zidovudine: five years later. Ann Intern Med 1992, 117:487-501.
22. Abu-ata O, Slim J, Perez G, Smith SM: HIV therapeutics: past, present, and future. Adv Pharmacol 2000, 49:1-40.
23. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States Washington, Department of Health and Human Services and the Henry J. Kaiser Foundation 2004.
24. Rojanapithayakorn W, Hanenberg R: The 100% condom program in Thailand. Aids 1996, 10:1-7.
25. Valdiserri RO, Ogden LL, McCray E: Accomplishments in HIV prevention science: implications for stemming the epidemic. Nat Med 2003, 9:881-886.
26. Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, Gopal R, Ojwiya A, Hughes P, Carpenter LM, Whitworth J: Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet 2003, 361:645-652.
27. Morison L, Weiss HA, Buve A, Carael M, Abega SC, Kaona F, Kanhonou L, Chege J, Hayes RJ: Commercial sex and the spread of HIV in four cities in sub-Saharan Africa. Aids 2001, 15 Suppl 4:S61-9.
28. Jha P, Nagelkerke NJD, Ngugi EN, Prasada Rao JVR, Willbond B, Moses S, Plummer FA: PUBLIC HEALTH: Reducing HIV Transmission in Developing Countries. Science 2001, 292:224-225.
29. Mandell GL, Bennett JE, Dolin R: Principles and Practices of Infectious Diseases. Philadelphia, Churchill Livingstone 2000., 5th